All News

Results from NCI-MATCH support the feasibility and efficiency of using next-generation sequencing (NGS) to triage patients to investigational therapy, provided that a sufficiently large pool of agents is made available.

Researchers found that Black non-Hispanic patients with head and neck cancer present with later stage at diagnosis and receive less treatment following their diagnosis compared to patients in all other racial and ethnic groups.

Treatment with trilaciclib prior to chemotherapy was found to significantly reduce the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer, compared with placebo.

A phase 1/2 nonrandomized clinical trial in patients with advanced anthracycline-naïve sarcoma indicated that the treatment combination was well tolerated in this patient population.

New research from NCI-MATCH support the feasibility and efficiency of using next-generation sequencing (NGS) to triage patients to investigational therapy, given that a sufficiently large pool of agents is provided.

This study indicated that the financial hardship associated with cancer-related employment disruption among female adolescent and young adults can be sizable, suggesting a need for interventions to aid this patient population.

The FDA accepted and granted priority review to the supplemental new drug application for osimertinib (Tagrisso) for the adjuvant treatment of patients with early-stage EGFR-mutated non-small cell lung cancer after complete tumor resection with curative intent.

A recent examination of breast cancer subtypes, specifically luminal A and luminal B breast cancer, found that incidence rates from 2010-2016 increased for a number of racial/ethnic and age groups.

Pretreatment circulating tumor DNA was found to be a reliable indicator of patient outcome for those with metastatic melanoma in the first-line immune checkpoint inhibitor (ICI) treatment setting, but not in the second-line setting.

Merck announced positive data regarding 2 studies, one examining pembrolizumab in combination with chemotherapy and another in combination with quavonlimab in combination to treat advanced non-small cell lung cancer.

The combination regimen demonstrated improved progression-free and overall survival in patients with previously untreated advanced RCC, according to results from the phase 3 CheckMate-9ER trial.

Following the new ASCCP-led national consensus guidelines for managing abnormal cervical cancer screening tests, these new guidelines estimate risk based on an individual’s risk factors, thus allowing for more personalized care management.

The researchers hypothesized “that serum PD-L1 may identify a subgroup of patients with HER2-positive [metastatic breast cancer] who may benefit the most from the addition of novel immunotherapies to trastuzumab.”

A study published in the Annals of Oncology suggests a better method involving tumor gene tests for estimating the survival of women with aggressive ovarian cancers.

Researchers indicated that this economic evaluation supports the widespread adoption of standard genetic testing for newly diagnosed patients with metastatic gastrointestinal stromal tumors.

This is the first study to demonstrate how a national insurer’s voluntary pay-for-performance program can successfully alter prescribing patterns among oncologists in order to provide higher-quality cancer care.

The FDA granted regular approval to venetoclax (Venclexta) in combination with azacitidine, decitabine, or low-dose cytarabine for adults 75 years or older with newly diagnosed acute myeloid leukemia, or who those have comorbidities precluding intensive induction chemotherapy.

Researchers indicated that these “findings are of direct clinical relevance and may help clinicians choose an optimal anti-myeloma regimen for patients with high-risk cytogenetic factors.”

With today being National Mammography Day, here are the latest updates in mammography research.

The breast cancer expert discussed the changes he has made in treating this patient population as a result of the COVID-19 pandemic.

The phase 3 ASTRAL-2 and ASTRAL-3 clinical studies evaluated the efficacy and safety of guadecitabine in adults with previously treated acute myeloid leukemia, and with previously treated myelodysplastic syndromes or chronic myelomonocytic leukemia, respectively.

A third data cut-off reassessment by the German Institute for Quality and Efficiency in Health Care found enzalutamide provided an added benefit for patients with high-risk non-metastatic castration-resistant prostate cancer.

The study established 4 cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) alone as the new standard approach for the majority of patients with limited-stage diffuse large B-cell lymphoma.

This phase 1 study found that vorinostat (Zolinza) in combination with either sirolimus (Rapamune) or everolimus (Afinitor) demonstrated clinical efficacy in patients with relapsed and/or refractory Hodgkin lymphoma and warrants further investigation.

The FDA approved an expanded label for pembrolizumab (Keytruda) as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.

New research reported that guidelines to reduce the number of opioids prescribed to patients following surgery may be missing a small group of patients that need a greater level of pain control.

This study found that immune checkpoint inhibitor therapy in patients with cancer could aggravate cardiovascular inflammation and subsequent cardiovascular or cerebrovascular events.

The study is evaluating copanlisib (Aliqopa) in combination with rituximab (Rituxan) in patients with indolent non-Hodgkin’s lymphoma who have relapsed after 1 or more prior lines of rituximab-containing therapy.

The latest episode of Oncology Peer Review On-The-Go explores an article from the September issue of the journal ONCOLOGY regarding the psychological states of patients enrolling in phase 1 clinical trials.

After adjustments for a number of clinical factors and factors related to access to care, the overall survival disparity among men undergoing radical prostatectomy was significantly decreased, but not eliminated, for Black men.